Neurological and Related Adverse Events Associated with Pharmacokinetic Interactions of Illicit Substances of Fungal Origin with Clinical Drugs
July 15, 2021 Julia M. Salamat, Kodye L. Abbott, Patrick Flannery et al.
This chapter reviews psychoactive illicit substances of fungal origin, focusing on psilocybin, the hallucinogenic compound in 'magic mushrooms' from genera such as Conocybe, Gymnopilus, Panaeolus, Pluteus, and Psilocybe. It describes neurological and related adverse events that can result from pharmacokinetic interactions between these fungal substances and clinical drugs in humans. The chapter also outlines directions for future research to better understand the underlying mechanisms of these adverse events.